POSA15 Evaluation of Efficacy and Safety of Nivolumab and Pembrolizumab in Elderly Cancer Patients

Abstract

Authors

HS Kim

Full Text Cite This Article
Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×